Cure My Disease
Don't miss your cure!
Please sign in to follow a disease.
Clinical trials sponsored by Chenxiaochun, explained in plain language.
This phase 2 trial investigates whether ozanimod, an oral drug that regulates the immune system, can reduce brain amyloid plaques and inflammation in people with moderate Alzheimer's disease. Forty participants aged 55 to 80 will receive either ozanimod or standard Alzheimer's me…
Phase: PHASE2 • Sponsor: ChenXiaoChun • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC